Immutep Starts Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma

 

• Soft tissue sarcoma, an orphan disease, represents a high unmet medical need with a poor prognosis
• First time efti will be studied in neoadjuvant, non-metastatic cancer setting
• Novel triple combination of efti with radiotherapy and anti-PD-1 therapy has potential to generate a robust anti-tumour immune response

https://www.biospace.com/article/releases/immutep-announces-initiation-of-investigator-initiated-phase-ii-trial-in-soft-tissue-sarcoma-in-neoadjuvant-setting/